Brazil tightens successful malaria campaign:
This article was originally published in Clinica
Executive Summary
Brazil has reported significant successes in its malaria control programme, two years after its launch. During a recent meeting to approve plans to strengthen the programme, the Brazilian healthcare foundation - Fundacao Nacional de Saude (Funasa) - reported a 70% fall in the incidence of malaria since 1999 across the Amazonia Legal region. Of the eight states in the region, Mato Grosso and Roraima recorded the highest falls, at 76.9% and 74.9%, respectively. the success has been attributed to a significant investment in epidemiological surveillance. The incidence of the disease remains high, however. In the year to August, 186,100 cases had been reported across the region this year. Funasa estimates that around 300,000 new cases will be diagnosed in 2002, compared with 387,200 in 2001 and 635,600 in 1999. The malaria plan was launched in July 2000, backed by annual funding totalling R$146m (US$37m).
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.